Search

Dr. Mao leads a team of integrative medicine specialists who offer complementary therapies such as massage and acupuncture to patients and caregivers.

… Friday, November 11, 2016 Summary As Chief of the Integrative Medicine Service at MSK, Jun Mao oversees a unique offering of services for patients, including acupuncture , music and dance therapy, nutrition counseling , and more. Jun Mao recently joined MSK as Chief of the Integrative Medicine Service

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal residual disease (MRD) responses compared to VRd alone in patients with newly diagnosed, transplant-ineligible multiple myeloma.

… Monday, February 17, 2025 UPDATE January 27, 2026: The U.S. Food and Drug Administration (FDA)  approved  the quadruplet therapy daratamumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of adult patients with newly

Memorial Sloan Kettering Cancer Center (MSK) will further enhance its ability to offer top cancer care to even more patients with the establishment of a freestanding, state-of-the-art outpatient treatment center in Bergen County, New Jersey. Residents from communities across northern New Jersey and southern New York State will have easier access to MSK’s unique expertise when MSK Bergen becomes fully operational in winter 2017.

… Tuesday, May 10, 2016 Memorial Sloan Kettering Cancer Center (MSK) will further enhance its ability to offer top cancer care to even more patients with the establishment of a freestanding, state-of-the-art outpatient treatment center in Bergen County, New Jersey. Residents from communities across northern

Could an implantable IUD help detect cancer early, when it is most curable? Scientists at the Sloan Kettering Institute are betting yes.

… Tuesday, September 21, 2021 Imagine a device like an Apple Watch that could detect cancer in its earliest stages. The device would communicate with a tiny nanosensor, implanted in your body, that screens for the presence of cancer-associated markers. If any are detected, the sensor sends a signal to

Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation proudly announce that eight distinguished MSK nurses and one nursing team were honored with the 2024 Robbins Family Award for Nursing Excellence. The awards coincide with National Nurses Week (May 6 – 12).

… Friday, May 10, 2024 Memorial Sloan Kettering Cancer Center (MSK) and the Robbins Family Foundation proudly announce that eight distinguished MSK nurses and one nursing team were honored with the 2024 Robbins Family Award for Nursing Excellence. The awards coincide with National Nurses Week (May 6 –

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Wednesday, January 31, 2024 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Selwyn Vickers Elected to the Fellows of the American Association for Cancer Research Academy Selwyn M. Vickers, MD, FACS , President and CEO, was  elected to the Fellows of the American

Read up on the latest developments in several key areas of cancer research, including genomic mapping, disease modeling through CRISPR, CAR T therapy, and cancer stem cells.

… Monday, April 16, 2018 Summary Memorial Sloan Kettering researchers are featured in more than 150 abstracts and events at this year’s American Association for Cancer Research annual meeting. Their scientific contributions are advancing understanding of all types of cancer. Memorial Sloan Kettering scientists

Read why MSK’s medical team is the best in the nation at treating gynecologic cancers.

… Tuesday, July 30, 2019 Summary Learn why our specialists are among the best in the world at treating cervical cancer , uterine (endometrial) cancer , and ovarian cancer . In its 2019–2020 listing of the nation’s best hospitals, U.S. News & World Report  ranks Memorial Sloan Kettering as number one for

Combining checkpoint blockade with engineered T cells may lead to longer-lasting results in patients with breast cancer, lung cancer, and other solid tumors.

… Thursday, July 28, 2016 Summary Memorial Sloan Kettering is a leader in developing immunotherapies to treat cancer. Now researchers say combining two different immune approaches may better treat solid tumors. The immunotherapy treatment known as CAR T cell therapy , while still experimental, is showing

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.

… Monday, September 9, 2019 Bottom Line: Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer